Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Leases Long-Term Debt Issuances Long-Term Debt Repayments Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Preferred Shares Issued Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Revenue - Other Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt issuances

Cartesian Therapeutics (RNAC) Shares Issued (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Shares Issued for 12 consecutive years, with $15.4 million as the latest value for Q1 2026.

For Q1 2026, Shares Issued changed N/A year-over-year to $15.4 million; the TTM value through Mar 2026 reached $15.4 million, changed N/A, while the annual FY2024 figure was $2.9 million, N/A changed from the prior year.
Shares Issued hit $15.4 million in Q1 2026 for Cartesian Therapeutics, up from -$273000.0 in the prior quarter.
Across five years, Shares Issued topped out at $9.4 billion in Q2 2022 and bottomed at -$121.6 million in Q4 2024.
Average Shares Issued over 5 years is $1.5 billion, with a median of $273000.0 recorded in 2025.
Year-over-year, Shares Issued surged 10585356.18% in 2022 and then plummeted 52523.81% in 2024.
Cartesian Therapeutics' Shares Issued stood at $36.7 million in 2022, then plummeted by 100.63% to -$231000.0 in 2023, then tumbled by 52523.81% to -$121.6 million in 2024, then surged by 99.78% to -$273000.0 in 2025, then skyrocketed by 5738.1% to $15.4 million in 2026.
According to Business Quant data, Shares Issued over the past three periods came in at $15.4 million, -$273000.0, and $273000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.